[HTML][HTML] Current and future therapies for inherited cholestatic liver diseases
WL Van Der Woerd, RHJ Houwen… - World Journal of …, 2017 - ncbi.nlm.nih.gov
Familial intrahepatic cholestasis (FIC) comprises a group of rare cholestatic liver diseases
associated with canalicular transport defects resulting predominantly from mutations in …
associated with canalicular transport defects resulting predominantly from mutations in …
Molecular mechanisms of neurodegeneration in spinal muscular atrophy
S Ahmad, K Bhatia, A Kannan… - Journal of …, 2016 - journals.sagepub.com
Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease with a high
incidence and is the most common genetic cause of infant mortality. SMA is primarily …
incidence and is the most common genetic cause of infant mortality. SMA is primarily …
A deep learning approach to identify gene targets of a therapeutic for human splicing disorders
Pre-mRNA splicing is a key controller of human gene expression. Disturbances in splicing
due to mutation lead to dysregulated protein expression and contribute to a substantial …
due to mutation lead to dysregulated protein expression and contribute to a substantial …
[HTML][HTML] Rescue of a familial dysautonomia mouse model by AAV9-Exon-specific U1 snRNA
G Romano, F Riccardi, E Bussani, S Vodret… - The American Journal of …, 2022 - cell.com
Familial dysautonomia (FD) is a currently untreatable, neurodegenerative disease caused
by a splicing mutation (c. 2204+ 6T> C) that causes skipping of exon 20 of the elongator …
by a splicing mutation (c. 2204+ 6T> C) that causes skipping of exon 20 of the elongator …
Correction of a cystic fibrosis splicing mutation by antisense oligonucleotides
Cystic fibrosis (CF), the most common life‐threatening genetic disease in Caucasians, is
caused by∼ 2,000 different mutations in the CF transmembrane conductance regulator …
caused by∼ 2,000 different mutations in the CF transmembrane conductance regulator …
Therapeutic activity of modified U1 core spliceosomal particles
ME Rogalska, M Tajnik, D Licastro, E Bussani… - Nature …, 2016 - nature.com
Modified U1 snRNAs bound to intronic sequences downstream of the 5′ splice site correct
exon skipping caused by different types of mutations. Here we evaluate the therapeutic …
exon skipping caused by different types of mutations. Here we evaluate the therapeutic …
RNA therapeutics: how far have we gone?
MF Coutinho, L Matos, JI Santos, S Alves - The mRNA Metabolism in …, 2019 - Springer
In recent years, the RNA molecule became one of the most promising targets for therapeutic
intervention. Currently, a large number of RNA-based therapeutics are being investigated …
intervention. Currently, a large number of RNA-based therapeutics are being investigated …
The progress of AAV-mediated gene therapy in neuromuscular disorders
S Aguti, A Malerba, H Zhou - Expert opinion on biological therapy, 2018 - Taylor & Francis
Introduction: The well-defined genetic causes and monogenetic nature of many
neuromuscular disorders, including Duchenne muscular dystrophy (DMD) and spinal …
neuromuscular disorders, including Duchenne muscular dystrophy (DMD) and spinal …
Rescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA
I Donadon, E Bussani, F Riccardi… - Nucleic acids …, 2019 - academic.oup.com
Abstract Spinal Muscular Atrophy results from loss-of-function mutations in SMN1 but
correcting aberrant splicing of SMN2 offers hope of a cure. However, current splice therapy …
correcting aberrant splicing of SMN2 offers hope of a cure. However, current splice therapy …
Motor neuron gene therapy: lessons from spinal muscular atrophy for amyotrophic lateral sclerosis
AP Tosolini, JN Sleigh - Frontiers in molecular neuroscience, 2017 - frontiersin.org
Spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) are severe nervous
system diseases characterized by the degeneration of lower motor neurons. They share a …
system diseases characterized by the degeneration of lower motor neurons. They share a …